Wednesday, 1 July 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 01 July 2026
News

Butler won't overrule PBS delisting

Posted 1 July 2026 PM

Health Minister Mark Butler has failed to rule out a proposed savage 40 per cent price cut that could see two major drugs that treat almost half of Australian patients with MS pulled from the PBS - instead he's flicked the problem to the PBAC.

At an early morning doorstop in Canberra today, the Minister said he was "deeply concerned" that Roche's Ocrevus and Novartis' Kesimpta could be delisted. 

To see the whole article, please login

Popular

Troubled drug faces revocation
J&J argues against 'far greater evil'
The PBS at its best, Mark. Really?
Cancer patients pick No. 1 pharma
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (22)

Access & Reimbursement (2)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home